当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.

Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.

Abstract：

:Atypical chronic myeloid leukemia (aCML) and chronic neutrophilic leukemia (CNL) are rare BCR-ABL1 fusion gene-negative myeloid neoplasms with a predominance of neutrophils. Since no standard therapeutic strategy currently exists for these diseases, we retrospectively evaluated the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aCML and CNL. Data from 14 aCML and 5 CNL patients as their diagnoses were collected using a nationwide survey. Allo-HSCT was performed between 2003 and 2014. Preconditioning regimens included myeloablative (n = 15), reduced-intensity (n = 3), and non-myeloablative (n = 1) regimens. Transplanted stem cells were obtained from HLA-matched related donors (n = 5) and alternative donors (n = 14). Neutrophil engraftment was successfully achieved in 17 patients. One-year overall survival rates (OS) were 54.4% (95% confidence interval [CI], 24.8 to 76.7%) and 40.0% (95% CI, 5.2 to 75.3%) in patients with aCML and CNL, respectively. Among aCML patients, 1-year OS were 76.2% (95% CI, 33.2 to 93.5%) and 20.0% (95% CI, 0.8 to 58.2%) in patients with <5% myeloblasts (n = 9) and ≥5% myeloblasts (n = 5) in peripheral blood before allo-HSCT, respectively. These results suggest that allo-HSCT achieves long-term survival in patients with aCML and CNL. Better pre-transplant management is required to improve the outcomes of aCML patients with ≥5% blasts in peripheral blood.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Itonaga H,Ota S,Ikeda T,Taji H,Amano I,Hasegawa Y,Ichinohe T,Fukuda T,Atsuta Y,Tanizawa A,Kondo T,Miyazaki Y

doi

10.1016/j.leukres.2018.11.003

subject

Has Abstract

pub_date

2018-12-01 00:00:00

pages

50-57

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(18)30464-8

journal_volume

75

pub_type

杂志文章

相关文献

LEUKEMIA RESEARCH文献大全
  • Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.

    abstract：:Prospective data are needed to ascertain the impact of iron chelation therapy in patients with myelodysplastic syndromes. The present 5-year prospective registry analysis was conducted to compare clinical outcomes between chelated and nonchelated patients with lower-risk myelodysplastic syndromes and transfusional iro...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2017.01.033

    authors： Lyons RM,Marek BJ,Paley C,Esposito J,McNamara K,Richards PD,DiBella N,Garcia-Manero G

    更新日期：2017-05-01 00:00:00

  • Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.

    abstract：:Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied. In a total of 49 patients, the MEP regime...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/s0145-2126(01)00114-x

    authors： Murohashi I,Kashimura T,Tominaga K,Wakao D,Takahashi T,Akiba M,Kishimoto K,Yoshida K,Yagasaki F,Itoh Y,Sakata T,Kawai N,Itoh K,Suzuki T,Matsuda A,Hirashima K,Bessho M

    更新日期：2002-03-01 00:00:00

  • Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data.

    abstract：:Secondary acute lymphoblastic leukemia (s-ALL) is rare and poorly defined and data regarding outcomes post-transplant are lacking. Here, we report a detailed analysis of s-ALL at our Institution. Among 211 eligible patients with ALL from 2006 to 2017, 30 (14%) were defined as s-ALL and the remaining as primary ALL (p-...

    journal_title：Leukemia research

    pub_type： 杂志文章,meta分析,评审

    doi：10.1016/j.leukres.2018.07.024

    authors： Ferraro F,Gao F,Stockerl-Goldstein K,Westervelt P,DiPersio JF,Ghobadi A

    更新日期：2018-09-01 00:00:00

  • A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

    abstract：:Mutations in Janus kinase 2 (JAK2) are implicated in the pathogenesis of Philadelphia-chromosome negative myeloproliferative neoplasms, including primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Gandotinib (LY2784544), a potent inhibitor of JAK2 activity, shows increased potency for the JAK2V61...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2017.08.010

    authors： Verstovsek S,Mesa RA,Salama ME,Li L,Pitou C,Nunes FP,Price GL,Giles JL,D'Souza DN,Walgren RA,Prchal JT

    更新日期：2017-10-01 00:00:00

  • Unusual course of an acute lymphoblastic leukemia case with i(9q) as a sole cytogenetic abnormality.

    abstract：:Chromosomal changes are necessary in determining the classification, prognosis and using the appropriate therapeutic regimen in acute leukemia. Isochromosomes are uncommon chromosome aberations in childhood acute lymphoblastic leukemia (ALL) and the effect of i(9q) is not well established. We present an 8-year-old mal...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.02.018

    authors： Cogulu O,Karapinar DY,Karaca E,Aydinok Y,Ozkinay F

    更新日期：2006-11-01 00:00:00

  • Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.

    abstract：BACKGROUND:Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders, with very different prognosis in given individuals; age and comorbidities are emerging as relevant patient-related factors influencing clinical outcome in MDS. Our aim was to evaluate the impact of age, comorbidities and disease s...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.05.007

    authors： Balleari E,Salvetti C,Del Corso L,Filiberti R,Bacigalupo A,Bellodi A,Beltrami G,Bergamaschi M,Berisso G,Calzamiglia T,Carella AM,Cavalleri M,Da Col A,Favorini S,Forni GL,Goretti R,Miglino M,Mitscheuning L,Molinari E,

    更新日期：2015-08-01 00:00:00

  • Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.

    abstract：:Forty patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) preceded by MDS were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study. They were given two cycles of cytarabine 100 mg/m with 12-h intervals on days 1-7 and idarubicin 12...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/s0145-2126(96)00116-6

    authors： Ruutu T,Hänninen A,Järventie G,Koistinen P,Koivunen E,Kätkä K,Nousiainen T,Oksanen K,Pelliniemi TT,Remes K,Timonen T,Volin L,Elonen E

    更新日期：1997-02-01 00:00:00

  • Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2.

    abstract：:Inhibition of cyclooxygenase 2 (COX-2) by the selective COX-2 inhibitor celecoxib has been suggested as potentially useful for B-cell lymphoma therapy. However, additional pharmacological activities of celecoxib have been discovered and have challenged the notion that its antitumor effects are mediated primarily via t...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.09.028

    authors： Chen ST,Thomas S,Gaffney KJ,Louie SG,Petasis NA,Schönthal AH

    更新日期：2010-02-01 00:00:00

  • HL-R5 and HL-D4: two differentiation resistant HL-60 variants.

    abstract：:A wide range of different agents are capable of inducing the onset of HL-60 differentiation along the myeloid lineage. The diversity of these agents has made the analysis of the molecular mechanisms involved in the regulation of the onset and progress of terminal differentiation in these cells difficult. We have adapt...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(89)90081-7

    authors： Darling DC,Linskens MH,Farzaneh F

    更新日期：1989-01-01 00:00:00

  • CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.

    abstract：:CD200 is a relatively ubiquitously expressed molecule that plays a role in cancer immune evasion through interaction with its receptors. High expression levels of CD200 have been described in different human malignancies. For example, CD200 has been shown to be targeted after RAS/RAF/MEK/ERK activation in melanoma. He...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2013.08.006

    authors： Conticello C,Giuffrida R,Parrinello N,Buccheri S,Adamo L,Sciuto MR,Colarossi C,Aiello E,Chiarenza A,Romano A,Salomone E,Gulisano M,Giustolisi R,Di Raimondo F

    更新日期：2013-12-01 00:00:00

  • Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.

    abstract：:The amplified myeloma centrosome has been identified as a therapeutic target. The present study explored the expression and prognostic significance of the centrosome-associated protein PLK1 in myeloma and the effect of BI 2536, a potent and selective inhibitor of PLK1, on myeloma cells. High plasma cell expression of ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2011.07.016

    authors： Evans RP,Dueck G,Sidhu R,Ghosh S,Toman I,Loree J,Bahlis N,Klimowicz AC,Fung J,Jung M,Lai R,Pilarski LM,Belch AR,Reiman T

    更新日期：2011-12-01 00:00:00

  • Risk-based combined-modality therapy of pediatric Hodgkin's lymphoma: a retrospective study.

    abstract：:We conducted a retrospective analysis to investigate the clinical outcome of combined-modality therapy using multiagent chemotherapy and involved-field radiotherapy in treatment of children with Hodgkin's lymphoma. Fifty eight cases with newly diagnosed Hodgkin's lymphoma were analyzed. The median follow-up duration w...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2010.06.012

    authors： Ali A,Sayed H,Farrag A,El-Sayed M

    更新日期：2010-11-01 00:00:00

  • Cytogenetic and DNA-flow cytometric studies of separated blasts.

    abstract：:With Percoll density gradients, blasts from peripheral blood and bone marrow could be separated with a significant enrichment, and very often with a high degree of purity. This allowed a study of selected cases, where the separated sample exhibited chromosome abnormalities and/or an abnormal DNA content distribution (...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(85)90037-2

    authors： Berneman ZN,De Bock R,Van Alsenoy L,Vingerhoets W,Van den Bergh M,Dumon J,Peetermans M

    更新日期：1985-01-01 00:00:00

  • Loss of heterozygosity and heterogeneity of its appearance and persisting in the course of acute myeloid leukemia and myelodysplastic syndromes.

    abstract：:Screening for loss of heterozygosity (LOH) of the panel of 18 highly polymorphic microsatellite markers, especially from the region 11p15, was carried out on 154 samples from 26 patients with acute myeloid leukemia and eight with myelodysplastic syndromes (MDS). LOH was detected at the majority (72%) of the loci teste...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(00)00086-2

    authors： Krsková-Honzátková L,Cermák J,Sajdová J,Starý J,Sedlácek P,Sieglová Z

    更新日期：2001-01-01 00:00:00

  • Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution.

    abstract：:The aim of this study was to describe the presenting features, the frequency and outcome of myeloid sarcoma (MS) diagnosed in our Institution from January 1995 to December 2000. Twelve MS were seen and the frequency account for only 2% of all acute myeloid leukemia (AML) patients observed in our department in the same...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2004.01.022

    authors： Breccia M,Mandelli F,Petti MC,D'Andrea M,Pescarmona E,Pileri SA,Carmosino I,Russo E,De Fabritiis P,Alimena G

    更新日期：2004-11-01 00:00:00

  • Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia.

    abstract：:Essential thrombocythemia (ET) is an uncommon chronic myeloproliferative disorder with no cure. Patients with ET are at risk of different complications, and currently there are no optimal prognostic standards to predict severe post-diagnosis complications such as thrombosis and hemorrhage. In this study, we retrospect...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2018.03.013

    authors： Zhou D,Chen W,Cheng H,Qiao JL,Zhu LL,Li ZY,Xu KL

    更新日期：2018-06-01 00:00:00

  • Leukotrienes and lipoxins--new potential performers in the regulation of human myelopoiesis.

    abstract：:Leukotrienes and lipoxins are bioactive lipoxygenase products formed by leukocytes alone or in collaboration with other cells. While the physiological role of lipoxins remains to be clarified, accumulating evidence shows that leukotrienes are important mediators in asthma and inflammation. Consequently, recent clinica...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/0145-2126(94)90053-1

    authors： Stenke L,Reizenstein P,Lindgren JA

    更新日期：1994-10-01 00:00:00

  • Decreased blood flow to rat bone marrow, bone, spleen, and liver in acute leukemia.

    abstract：:An acute promyelocytic leukemia in the rat (BNML) has been used in model studies on pathogenesis and therapy of human acute myeloid leukemia. The blood supply to bone marrow during BNML development has hitherto not been examined, even though in general, blood flow to hematopoietic tissues might affect drug treatment a...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(93)90071-r

    authors： Iversen PO,Thing-Mortensen B,Nicolaysen G,Benestad HB

    更新日期：1993-08-01 00:00:00

  • The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes.

    abstract：:During 2004-2006, two hypomethylating agents (HMAs) were approved for the treatment of myelodysplastic syndromes (MDS) in the United States. We assessed the impact of HMAs on the cost of care and survival of MDS patients, by constructing a cohort of patients who were diagnosed during 2001-2007 (n=6556, age ≥66.5 years...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.07.020

    authors： Wang R,Gross CP,Frick K,Xu X,Long J,Raza A,Galili N,Zikria J,Guan Y,Ma X

    更新日期：2012-11-01 00:00:00

  • Dequalinium induces cytotoxicity in human leukemia NB4 cells by downregulation of Raf/MEK/ERK and PI3K/Akt signaling pathways and potentiation of specific inhibitors of these pathways.

    abstract：:Delocalized lipophilic cation dequalinium (DQA) selectively accumulates in mitochondria and displays anticancer activity in different malignancies. Our previous studies indicate a DQA-induced cytotoxicity in human acute promyelocytic leukemia NB4 cells by early disturbance in mitochondrial function and oxidative stres...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2014.01.009

    authors： García-Pérez AI,Galeano E,Nieto E,Estañ MC,Sancho P

    更新日期：2014-07-01 00:00:00

  • Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia.

    abstract：:Despite advances in understanding the complexities of acute myeloid leukaemia (AML), the treatment of refractory or relapsed AML (rrAML) remains a daunting clinical challenge. Numerous clinical trials have failed to identify new treatments or combinations of existing therapies that substantially improve outcomes and s...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2016.05.025

    authors： Kell J

    更新日期：2016-08-01 00:00:00

  • DNA and RNA analysis by flow cytometry of the leukemia in AKR mice.

    abstract：:The development of the leukemia-lymphoma complex was studied in AKR/J (H-2k) mice using flow cytometry and staining with acridine orange. Investigation of cytokinetics and of cellular RNA content showed that during the neonatal period all mice had a significant increase of S phase cells in the thymus, bone marrow, lym...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(85)90158-4

    authors： Wustrow TP,Andreeff M,Fernandes G,Good RA

    更新日期：1985-01-01 00:00:00

  • BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients.

    abstract：:The Bcl-2 protein inhibits apoptosis (programmed cell death) of hematopoietic stem cells induced by a variety of noxious stimuli, thus mediating chemoresistance and decreasing chemosensitivity. Higher Bcl-2 expression correlates to an adverse outcome following therapy for acute myeloid leukemia (AML). The current stud...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.05.009

    authors： Moon JH,Sohn SK,Lee MH,Jang JH,Kim K,Jung CW,Kim DH

    更新日期：2010-02-01 00:00:00

  • Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo.

    abstract：:The treatment of acute leukemia is still challenging due in part to the development of resistance and relapse. This chemotherapeutics resistance is established by clonal selection of resistant variants of the cancer cells. Recently, a horizontal transfer of chemo-resistance among cancer cells via extracellular vesicle...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2017.09.014

    authors： Bouvy C,Wannez A,Laloy J,Chatelain C,Dogné JM

    更新日期：2017-11-01 00:00:00

  • Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation.

    abstract：:A retrospective analysis of the relationship between the initial classification according to either FAB or WHO criteria, the presence of risk factors and the type of therapy including stem cell transplantation (SCT) on the survival was performed in a group of 106 patients with primary myelodysplastic syndrome (MDS) of...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2003.10.016

    authors： Cermák J,Vítek A,Michalová K

    更新日期：2004-06-01 00:00:00

  • WITHDRAWN: The effect of dihydroartemisinin on TfR and VEGF expression in iron overload human myeloid leukemia K562 cells.

    abstract：:This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.01.006

    authors： Zengwang,Zhou HJ,Li A,Zhang JL

    更新日期：2009-02-20 00:00:00

  • Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia.

    abstract：:Although there has been much progress in the treatment of acute lymphoblastic leukemia (ALL), decreased sensitivity to chemotherapy remains a significant issue. Recent studies have shown how interactions with the bone marrow microenvironment can protect ALL cells from chemotherapy and allow for the persistence of the ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2017.01.030

    authors： Quagliano A,Gopalakrishnapillai A,Barwe SP

    更新日期：2017-05-01 00:00:00

  • LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.

    abstract：:Effects of the HDAC inhibitor LBH-589 (panobinostat) on fludarabine lethality toward acute myeloid leukemia (AML) cells were examined in vitro and in vivo. LBH-589 pretreatment sensitized U937, HL-60, and primary leukemia cells to fludarabine while blocking NF-κB activation accompanied by XIAP down-regulation and JNK ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2011.10.020

    authors： Rosato R,Hock S,Dent P,Dai Y,Grant S

    更新日期：2012-04-01 00:00:00

  • Remarkable expression of vascular endothelial growth factor in bone marrow plasma cells of patients with POEMS syndrome.

    abstract：:Vascular endothelial growth factor (VEGF) is pathognomonically elevated in patients with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) syndrome. However, its source of overproduction is unclear. As clinical improvement is almost always associated with VEGF reduction after...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2016.09.017

    authors： Wang C,Huang XF,Cai QQ,Cao XX,Cai H,Zhou D,Li J

    更新日期：2016-11-01 00:00:00

  • Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia.

    abstract：:The functional behavior of hematopoietic stem cell (HSC) and progenitors in chronic myelomonocytic leukemia (CMML) and on disease progression is little known. We performed cell proliferation, apoptosis, hematopoietic colony forming/replating and differentiation potential studies in the purified subpopulations of Lin(-...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.02.011

    authors： Sun Q,So CC,Yip SF,Wan TS,Ma SK,Chan LC

    更新日期：2008-09-01 00:00:00